Researchers discover potential treatment to reverse lung scarring

For decades, pulmonary fibrosis has been considered an irreversible condition.

While current medications like nintedanib and pirfenidone help slow down the disease, they cannot fix the damage that has already occurred.

By targeting proteins like interleukin-11 (IL-11) or inhibiting the YAP/TAZ proteins in immune cells, scientists have successfully stimulated tissue regeneration in laboratory models.

Nevertheless, the discovery that fibrosis is not biologically fixed represents a monumental shift in pulmonary medicine.